Final results from M72 AS01E TB Vaccine Trial
The final results from the M72AS01E TB vaccine study have been published in the New England Journal of Medicine. The vaccine demonstrated a 50% efficacy rate in the incidence of lung TB disease in HIV-negative adults, already infected with latent...
Beat TB drama production
Beat TB, a Welcome Trust funded street theater production which raised awareness about tuberculosis (TB) and vaccine research understanding amongst the broader public of the Worcester area. during 2016.
2018 Tb under the Spotlight Science Engagement
The “TB Under the Spotlight Science Engagement” programme was conceptualised and presented by South African Tuberculosis Vaccine Initiative (SATVI) with scientists from the Division of Molecular Biology and Human Genetics at Stellenbosch University...
New multi-functional TB blood test validated
Researchers the South African Tuberculosis Vaccine Initiative (SATVI), the Center for Global Infectious Disease Research(USA) and a large consortium of collaborators have developed a validated a new, simple blood-based test that has the potential to...
Community Engagement
Carina's Choice: SATVI collaborated with UCT Drama Department and Worcester Secondary School in developing this play which was performed by learners from Worcester Secondary School at 8 local high schools reaching approximately 8 000 adolescents in...


Monday, 25 January 2021
8 January 2020 Opinion Piece: Why I choose COVID-19 vaccination based on verifiable evidence

Professor Tom Scriba has written an opinion piece for News24 in which he explains the safety profile of the 3 available COVID-19 vaccines & the benefits of receiving it.

Publication Date:
Fri, 08 Jan 2021 - 14:15
4 January 2020 News: SATVI researcher awarded full IDM membership

Associate Professor Elisa Nemes has been appointed full member of the Institute of Infectious Disease and Molecular Medicine at the UCT Health Sciences Faculty.

Publication Date:
Wed, 06 Jan 2021 - 09:00
9 December 2020 ID93+GLA-SE candidate TB vaccine appears safe and immunogenic in treated TB patients

The results from the ID93+GLA-SE TB vaccine clinical trial have just been published in the Lancet Respiratory Medicine journal. The candidate vaccine displayed an acceptable safety profile and provides encouraging evidence of vaccine-induced immune responses when given to cured TB patients at the end of treatment.

Publication Date:
Wed, 09 Dec 2020 - 20:30
3 December 2020 Vacancy SATVI Project Manager

SATVI is seeking applications for a Project Manager who will manage clinical research projects within SATVI.    NOW CLOSED

Publication Date:
Thu, 03 Dec 2020 - 13:30